SCHEMBL30061382

SCHEMBL30061382

[2H]C([2H])([2H])O[C@H]1CN(C(=O)OCc2ccccc2)C[C@@H]1NC(=O)OC(C)(C)C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.54
KMT2A Q03164 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
PARP1 P09874 1/20 0.41
CTSL P07711 1/20 0.40
BACE1 P56817 1/20 0.40
BACE2 Q9Y5Z0 1/20 0.40
SYK P43405 1/20 0.40
CHRM4 P08173 1/20 0.40
CTSK P43235 1/20 0.40
USP30 Q70CQ3 1/20 0.40
CYP2C19 P33261 1/20 0.39
MEN1 O00255 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
PDK1 Q15118 1/20 0.39
PDK2 Q15119 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7498881 0.93 PDE4B (0.59) PDE4BKMT2AL3MBTL1HTTSMN1; SMN2
SCHEMBL30060223 0.93 PDE4B (0.59) PDE4BKMT2AL3MBTL1HTTSMN1; SMN2
SCHEMBL1360262 0.89 PDE4B (0.56) PDE4BKMT2AL3MBTL1HTTSMN1; SMN2
SCHEMBL1360264 0.89 PDE4B (0.56) PDE4BKMT2AL3MBTL1HTTSMN1; SMN2
SCHEMBL23938191 0.86 PDE4B (0.54) PDE4BKMT2AL3MBTL1HTTSMN1; SMN2
SCHEMBL20722589 0.86 PDE4B (0.54) PDE4BKMT2AL3MBTL1HTTSMN1; SMN2
SCHEMBL9051439 0.85 PDE4B (0.59) PDE4BKMT2AL3MBTL1HTTSMN1; SMN2
SCHEMBL24509184 0.85 PDE4B (0.59) PDE4BKMT2AL3MBTL1HTTSMN1; SMN2
SCHEMBL9053027 0.85 PDE4B (0.59) PDE4BKMT2AL3MBTL1HTTSMN1; SMN2
SCHEMBL15720211 0.85 PDE4B (0.59) PDE4BKMT2AL3MBTL1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12162888-B2 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2024-12-10 US disclosed
CN-112867712-B Carboxamide as ubiquitin-specific protease inhibitor 瓦洛早期发现股份有限公司 2024-07-16 CN disclosed
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2022-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 PDE4B 3612/4885KMT2A 339/4885L3MBTL1 1885/4885
US-12162888-B2 Carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 PDE4B 3612/4885KMT2A 339/4885L3MBTL1 1885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.